Skip to content
TrialScanner

NCT06153693

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Phase 3CompletedMLYSLead

Registry record

Lead sponsor
Mineralys Therapeutics Inc.
Conditions
Hypertension
Primary completion
Dec 10, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06153693 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06153693: Efficacy and Safety of... | TrialScanner